Summary
DexCom, Inc. (DXCM) presented its 2010 Form 10-K filing, detailing its progress as a medical device company focused on continuous glucose monitoring (CGM) systems. The company's primary product, the SEVEN PLUS system, is designed for ambulatory use by individuals with diabetes and saw increased sales volume and average selling prices in 2010 compared to 2009. Despite revenue growth, DexCom continued to incur significant operating losses, consistent with its early commercialization stage, with a reported net loss of $55.17 million for the year. The company is actively investing in research and development for next-generation products and exploring the in-hospital market with its GlucoClear system. Key financial and operational highlights include a substantial increase in product revenue to $40.2 million, driven by higher sales of the SEVEN PLUS system. However, the company's operating expenses, particularly in selling, general, and administrative functions, also rose significantly. DexCom secured additional funding through follow-on public offerings, raising approximately $66 million in 2010 to support its ongoing commercialization and development efforts. The company is also navigating significant legal challenges, including a patent infringement lawsuit with Abbott Diabetes Care, which poses a notable risk. Despite the ongoing losses, DexCom is positioning itself for future growth by expanding its sales force and advancing its technology platform.
Financial Highlights
46 data points| Revenue | $48.60M |
| Cost of Revenue | $30.20M |
| Gross Profit | $18.40M |
| R&D Expenses | $23.20M |
| SG&A Expenses | $40.50M |
| Operating Expenses | $63.70M |
| Operating Income | -$45.30M |
| Interest Expense | $1.50M |
| Net Income | -$55.20M |
| EPS (Basic) | $-0.24 |
| Shares Outstanding (Basic) | 227.60M |
Key Highlights
- 1Product revenue increased by over 120% from $18.0 million in 2009 to $40.2 million in 2010, driven by higher sales volume and average selling prices of the SEVEN PLUS system.
- 2The company incurred a net loss of $55.17 million in 2010, reflecting significant ongoing investment in research and development ($23.2 million) and selling, general, and administrative expenses ($40.5 million) to support commercialization.
- 3DexCom raised approximately $66 million in net proceeds from two follow-on public offerings in 2010, bolstering its cash position to $47.1 million (excluding restricted cash) as of year-end.
- 4Significant legal proceedings are ongoing with Abbott Diabetes Care regarding patent infringement, with potential implications for DexCom's product portfolio and business operations.
- 5The company is pursuing broader market penetration by expanding its direct sales force and exploring partnerships for its continuous glucose monitoring technology.
- 6DexCom's GlucoClear system, designed for in-hospital use, received CE Mark approval but generated minimal revenue, with continued efforts to gain FDA clearance.
- 7The company faces challenges related to third-party reimbursement, with most payors having restrictive coverage policies, impacting product adoption and revenue potential.